Agios: FDA extends mitapivat sickle cell disease review to February 2027
What happened? Agios Pharmaceuticals said on 30 October 2026 that the US FDA has extended the review deadline for its application to expand mitapivat, an oral medicine that boosts activity of the enzyme pyruvate kinase, to include sickle cell disease. The new decision date is 1 February 2027. Earlier in October the FDA asked for additional data to decide whether a Risk Evaluation and Mitigation Strategy (REMS) — a plan to manage specific safety risks — is needed; Agios responded on 19 October with roughly nine months of updated safety data from the ongoing RISE UP Phase 2 and Phase 3 trials, and the FDA classified the response as a major amendment, adding three months to the review.
Why it matters: Sickle cell disease is a rare inherited blood disorder affecting about 100,000 people in the US, in which misshapen red blood cells block blood vessels and cause severe pain and organ damage. Mitapivat is already approved in the US for two other anaemias (pyruvate kinase deficiency in 2022 and thalassaemia in 2025); the sickle cell application is under the FDA's accelerated approval pathway with Priority Review. Agios says it is launch-ready and reports no cases of liver injury of the type seen in other trials among treated sickle cell patients. A confirmatory Phase 3 trial (REIGNITE) testing mitapivat's effect on transfusion need dosed its first patient in July 2026.
Read more: BioSpace (GlobeNewswire), 30 October 2026